Background: Sudden Cardiac Death (SCD) remains a major public health concern, accounting for more than 50% of cardiac deaths. The majority of these deaths are related to ischemic heart disease, however increasingly recognized are non-ischemic causes such as cardiac channelopathies. Bradyarrhythmias and pulseless electrical activity comprise a larger proportion of out-ofhospital arrests than previously realized, particularly in patients with more advanced heart failure or noncardiac triggers such as pulmonary embolism. Patients surviving Sudden Cardiac Arrest (SCA) have a substantial risk of recurrence, particularly within 18 months post event. The timing of tachyarrhythmias complicating acute infarction has important implications regarding the likelihood of recurrence, with those occurring within 48 hours having a more favorable long-term outcome. In the absence of a clear reversible cause, implantable cardioverter defibrillators remain the mainstay in the secondary prevention of SCD. Post defibrillation electromechanical dissociation is common in patients with cardiomyopathy and can lead to SCD despite successful defibrillation of the primary tachyarrhythmia. Antiarrhythmic agents are highly effective in preventing recurrent arrhythmias in specific diseases such as the congenital long QT syndrome.
Conclusion: Catheter ablation is used most commonly to prevent recurrent ICD therapies in patients with structural heart disease-related ventricular arrhythmias, however recent publications have shown substantial benefit in other entities such as idiopathic ventricular fibrillation.
Keywords: Electrophysiologic considerations, cardioverter defibrillators (ICDs), coronary artery disease, mortality, sudden cardiac arrest, survival.
Genetics and Heart Failure: A Concise Guide for the Clinician
Current Cardiology Reviews Incidence and Prevalence of Hypothyroidism in Patients Affected by Chronic Heart Failure: Role of Amiodarone
Endocrine, Metabolic & Immune Disorders - Drug Targets Device Therapies: New Indications and Future Directions
Current Cardiology Reviews Function and Pharmacology of Spinally-Projecting Sympathetic Pre-Autonomic Neurones in the Paraventricular Nucleus of the Hypothalamus
Current Neuropharmacology Serelaxin: New Investigational Treatment in Acute Heart Failure
Cardiovascular & Hematological Agents in Medicinal Chemistry Survey of Mortality Due to Influenza A in North of Iran, 2015-2016
Current Respiratory Medicine Reviews Beta-Blockers as First Line Treatment of Hypertension: A Proponents View
Current Hypertension Reviews Nanotechnology and Treatment of Cardiovascular Disease: A Review of Nanoscale Innovations for Regenerative Therapy
Current Nanomedicine Chronic Heart Failure and Exercise Intolerance: The Hemodynamic Paradox
Current Cardiology Reviews Myocardial Tissue Engineering and Heart Muscle Repair
Current Pharmaceutical Biotechnology Cardioprotection by Targeting the Pool of Resident and Extracardiac Progenitors
Current Drug Targets Oxidative Stress During Myocardial Ischaemia and Heart Failure
Current Pharmaceutical Design Calcium Homeostasis and Kinetics in Heart Failure
Medicinal Chemistry Innate Immunity and the Heart
Current Pharmaceutical Design Tissue Engineering Techniques in Cardiac Repair and Disease Modelling
Current Pharmaceutical Design Inflammatory Arthritis and Heart Disease
Current Pharmaceutical Design Use of BNP and CRP as Biomarkers in Assessing Cardiovascular Disease:Diagnosis Versus Risk
Current Vascular Pharmacology Coenzyme Q10 in Cardiovascular and Metabolic Diseases: Current State of the Problem
Current Cardiology Reviews Gender-Specific Aspects in Primary and Secondary Prevention of Cardiovascular Disease
Current Pharmaceutical Design Heart Failure in Chronic Myocarditis: A Role for microRNAs?